

Hani Hassoun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3370548/publications.pdf>

Version: 2024-02-01

99
papers

1,283
citations

394421

19
h-index

395702

33
g-index

101
all docs

101
docs citations

101
times ranked

1911
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. <i>British Journal of Haematology</i> , 2022, 196, 105-109. | 2.5 | 30 |
| 2 | Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. <i>Haematologica</i> , 2022, 107, 284-286. | 3.5 | 4 |
| 3 | Nutrition perceptions, needs and practices among patients with plasma cell disorders. <i>Blood Cancer Journal</i> , 2022, 12, 70. | 6.2 | 7 |
| 4 | Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2022, 63, 2233-2237. | 1.3 | 3 |
| 5 | Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. <i>American Journal of Hematology</i> , 2022, 97, . | 4.1 | 4 |
| 6 | Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2160-2166. | 7.0 | 2 |
| 7 | Evaluating serum-free light chain ratio as a biomarker for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8047-8047. | 1.6 | 1 |
| 8 | African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8045-8045. | 1.6 | 4 |
| 9 | Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA4-LBA4. | 1.6 | 3 |
| 10 | Clinical efficacy of daratumumab (DARA)-based second line therapy after DARA-containing and DARA-free induction therapies in multiple myeloma: A single center experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20005-e20005. | 1.6 | 0 |
| 11 | Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study. <i>Leukemia and Lymphoma</i> , 2022, 63, 2760-2761. | 1.3 | 1 |
| 12 | Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 757-767. | 1.6 | 98 |
| 13 | Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m ²) in combination with lenalidomide and dexamethasone. <i>American Journal of Hematology</i> , 2021, 96, E193-E196. | 4.1 | 10 |
| 14 | Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8048-8048. | 1.6 | 1 |
| 15 | Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy. <i>Clinica Chimica Acta</i> , 2021, 516, 136-141. | 1.1 | 7 |
| 16 | Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e422-e432. | 4.6 | 50 |
| 17 | Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2021, 7, 862. | 7.1 | 63 |
| 18 | A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study. <i>Blood</i> , 2021, 138, 4759-4759. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms. <i>Blood</i> , 2021, 138, 3271-3271. | 1.4 | 1 |
| 20 | Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience. <i>Blood</i> , 2021, 138, 1644-1644. | 1.4 | 7 |
| 21 | Phase I First-in-Class Trial of MCarH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPCR5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 827-827. | 1.4 | 23 |
| 22 | Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures. <i>Blood</i> , 2021, 138, 4762-4762. | 1.4 | 0 |
| 23 | Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 204-208. | 2.0 | 10 |
| 24 | Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 198-200. | 0.4 | 17 |
| 25 | Accelerated single cell seeding in relapsed multiple myeloma. <i>Nature Communications</i> , 2020, 11, 3617. | 12.8 | 41 |
| 26 | COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. <i>Blood Cancer Discovery</i> , 2020, 1, 234-243. | 5.0 | 46 |
| 27 | Melflufen for relapsed and refractory multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1069-1078. | 4.1 | 17 |
| 28 | Incremental Value of Global Longitudinal Strain for Predicting Survival in Patients With Advanced AL Amyloidosis. <i>JACC: CardioOncology</i> , 2020, 2, 223-231. | 4.0 | 27 |
| 29 | Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2020, 189, 904-907. | 2.5 | 40 |
| 30 | Vitiligo Following Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e171-e173. | 0.4 | 2 |
| 31 | Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1394-1401. | 2.0 | 8 |
| 32 | HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis. <i>Blood</i> , 2020, 136, 41-43. | 1.4 | 3 |
| 33 | HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis. <i>Blood</i> , 2020, 136, 22-23. | 1.4 | 2 |
| 34 | HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients. <i>Blood</i> , 2020, 136, 44-46. | 1.4 | 2 |
| 35 | HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis. <i>Blood</i> , 2020, 136, 15-17. | 1.4 | 6 |
| 36 | HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).. <i>Journal of Clinical Oncology</i> , 2020, 38, e20570-e20570. | 1.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 18-19. | 1.4 | 0 |
| 38 | Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls. <i>Blood</i> , 2020, 136, 44-45. | 1.4 | 0 |
| 39 | A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study). <i>Blood</i> , 2020, 136, 8-10. | 1.4 | 0 |
| 40 | HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents. <i>Blood</i> , 2020, 136, 2-4. | 1.4 | 4 |
| 41 | HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations. <i>Blood</i> , 2020, 136, 20-22. | 1.4 | 0 |
| 42 | HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis. <i>Blood</i> , 2020, 136, 27-29. | 1.4 | 1 |
| 43 | VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup. <i>Blood</i> , 2020, 136, 37-38. | 1.4 | 1 |
| 44 | Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 7-7. | 1.4 | 1 |
| 45 | Association of Patient Activity Bioprofiles with Hrql and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 26-28. | 1.4 | 2 |
| 46 | VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis. <i>Blood</i> , 2019, 134, 1835-1835. | 1.4 | 7 |
| 47 | Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab. <i>Blood</i> , 2019, 134, 1883-1883. | 1.4 | 8 |
| 48 | Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2019, 134, 3127-3127. | 1.4 | 2 |
| 49 | A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis. <i>Blood</i> , 2019, 134, 3128-3128. | 1.4 | 4 |
| 50 | Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2019, 134, 862-862. | 1.4 | 34 |
| 51 | First Description of B Cell Maturation Antigen Expression in Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 5452-5452. | 1.4 | 5 |
| 52 | MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy. <i>Blood</i> , 2019, 134, 4377-4377. | 1.4 | 2 |
| 53 | Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 3060-3060. | 1.4 | 0 |
| 54 | Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis. <i>Blood</i> , 2019, 134, 4577-4577. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 5554-5554. | 1.4 | 0 |
| 56 | Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 871-876. | 2.0 | 35 |
| 57 | Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. <i>Leukemia and Lymphoma</i> , 2018, 59, 1981-1985. | 1.3 | 16 |
| 58 | Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. <i>Clinical Biochemistry</i> , 2018, 51, 66-71. | 1.9 | 49 |
| 59 | Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 221-224. | 1.3 | 12 |
| 60 | Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 64-70. | 2.8 | 41 |
| 61 | Multiple myeloma with simultaneous cutaneous and central nervous system involvement. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 2015-2016. | 0.5 | 1 |
| 62 | Identifying Ultra-High Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 3192-3192. | 1.4 | 1 |
| 63 | OP-106 Horizon " Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS. <i>Blood</i> , 2018, 132, 600-600. | 1.4 | 12 |
| 64 | Bone Marrow-Based and Longitudinal Blood-Based MRD Tracking in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd): A Correlative and Clinical Phase II Study. <i>Blood</i> , 2018, 132, 3281-3281. | 1.4 | 4 |
| 65 | Continuous Mobile Wearable Bio-Monitoring of Newly Diagnosed Multiple Myeloma Patients Undergoing Initial Chemotherapy. <i>Blood</i> , 2018, 132, 4751-4751. | 1.4 | 1 |
| 66 | MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m ²) in Combination with Lenalidomide and Dexamethasone. <i>Blood</i> , 2018, 132, 1983-1983. | 1.4 | 2 |
| 67 | Capture Rate of the Adaptive Next Generation Sequencing VDJ Assay in Multiple Myeloma. <i>Blood</i> , 2018, 132, 3184-3184. | 1.4 | 3 |
| 68 | Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial. <i>Blood</i> , 2018, 132, 959-959. | 1.4 | 71 |
| 69 | Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience. <i>Blood</i> , 2018, 132, 5591-5591. | 1.4 | 0 |
| 70 | Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 1823-1831. | 1.3 | 57 |
| 71 | Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2017, 58, 2962-2965. | 1.3 | 4 |
| 72 | Proteomic profiling in plasma cell disorders: a feasibility study. <i>Leukemia and Lymphoma</i> , 2017, 58, 1757-1759. | 1.3 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e431-e442. | 4.6 | 132 |
| 74 | Upfront use of plerixafor and granulocyte-colony stimulating factor (G-CSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency*. <i>Leukemia and Lymphoma</i> , 2017, 58, 1123-1129. | 1.3 | 11 |
| 75 | Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. <i>Blood</i> , 2016, 127, 2355-2356. | 1.4 | 13 |
| 76 | CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 258-267. | 2.0 | 21 |
| 77 | Whole Exome Sequencing from Nine Independent Sites of Extrasosseous Disease in a Single Patient with Relapsed Multiple Myeloma Show That Extramedullary Disease Arise through a Combination of Branched and Parallel Evolution. <i>Blood</i> , 2016, 128, 2090-2090. | 1.4 | 0 |
| 78 | Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 1785-1785. | 1.4 | 4 |
| 79 | Induction with Bortezomib and Dexamethasone (BD) Followed By Risk Adapted High Dose Melphalan and Autologous Stem Cell Transplantation and BD Consolidation in Patients with AL Amyloidosis: A Phase II Feasibility Study. <i>Blood</i> , 2015, 126, 3178-3178. | 1.4 | 1 |
| 80 | Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results. <i>Blood</i> , 2015, 126, 375-375. | 1.4 | 19 |
| 81 | Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy. <i>Blood</i> , 2015, 126, 4257-4257. | 1.4 | 8 |
| 82 | Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials. <i>Blood</i> , 2015, 126, 1975-1975. | 1.4 | 0 |
| 83 | Autologous Hematopoietic Stem Cell Transplantation Overcomes Primary Refractory Disease in Multiple Myeloma Patients Treated with Novel Agents. <i>Blood</i> , 2015, 126, 1996-1996. | 1.4 | 5 |
| 84 | A phase 2 single-center study of carfilzomib 56 mg/m ² with or without low-dose dexamethasone in relapsed multiple myeloma. <i>Blood</i> , 2014, 124, 899-906. | 1.4 | 73 |
| 85 | Upfront Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients: An Update on Cost Analysis Study at Memorial Sloan Kettering Cancer Center. <i>Blood</i> , 2014, 124, 848-848. | 1.4 | 1 |
| 86 | Efficacy and Risk Factors Analysis of Upfront Autologous Stem Cell Mobilization Using Plerixafor and Granulocyte-Colony Stimulating Factor (G-CSF) in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 3856-3856. | 1.4 | 0 |
| 87 | Multiple Copies of MLL Is The Most Commonly Detected Cytogenetic Abnormality In Newly Diagnosed Multiple Myeloma and May Modify Disease Risk. <i>Blood</i> , 2013, 122, 1910-1910. | 1.4 | 2 |
| 88 | Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2013, 122, 755-755. | 1.4 | 1 |
| 89 | T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation For Patients With Relapsed Multiple Myeloma and High-Risk Cytogenetics Permits Long-Lasting Remissions In The Absence Of Graft-Versus-Host Disease. <i>Blood</i> , 2013, 122, 2115-2115. | 1.4 | 0 |
| 90 | Osteomalacia due to adult Fanconi syndrome in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2011, 52, 536-538. | 1.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 91 | Treatment of Heparin-Induced Thrombocytopenia and Associated Thromboses with Fondaparinux.. Blood, 2009, 114, 2096-2096. | 1.4 | 1 |
| 92 | High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.. Blood, 2007, 110, 5113-5113. | 1.4 | 0 |
| 93 | Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. British Journal of Haematology, 2006, 132, 155-161. | 2.5 | 39 |
| 94 | Adjuvant Dexamethasone (D) ± Thalidomide (T) Improves Hematologic and Organ Responses after Risk-Adapted High-Dose Melphalan with Autologous Stem Cell Transplant (SCT) for Patients with Systemic AL Amyloidosis (AL).. Blood, 2005, 106, 1163-1163. | 1.4 | 3 |
| 95 | The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.. Blood, 2005, 106, 3481-3481. | 1.4 | 1 |
| 96 | Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.. Blood, 2005, 106, 1156-1156. | 1.4 | 0 |
| 97 | The Abdominal Fat Pad Aspirate for Diagnosing Amyloidosis Is a Useful Tool.. Blood, 2005, 106, 5107-5107. | 1.4 | 0 |
| 98 | Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.. Blood, 2004, 104, 2409-2409. | 1.4 | 2 |
| 99 | Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. Leukemia and Lymphoma, 0, , 1-10. | 1.3 | 1 |